Q97756066

Summary

Q97756066 is a committee group motion^[1].

Key Facts

• Q97756066 authored Christer Nylander^[2].
• Q97756066 authored Erik Bengtzboe^[3].
• Q97756066 authored Ulrika Heie^[4].
• Q97756066 authored Annika Eclund^[5].
• Q97756066's instance of is recorded as committee group motion^[6].
• Q97756066's part of the series is recorded as motions of 2017-2018 legislative session of the Riksdag^[7].
• Q97756066's language of work or name is recorded as Swedish^[8].
• Q97756066 was published on +2018-04-05T00:00:00Z^[9].
• Q97756066's main subject is medication^[10].
• Q97756066's work available at URL is recorded as http://data.riksdagen.se/dokument/H5024079^[11].
• Q97756066's work available at URL is recorded as http://data.riksdagen.se/dokumentstatus/H5024079^[12].
• Q97756066's applies to jurisdiction is recorded as Sweden^[13].
• Q97756066's legal citation of this text is recorded as Mot. 2017/18:4079^[14].
• Q97756066's title is recorded as med anledning av prop. 2017/18:193 Kompletterande bestämmelser om etisk granskning till EU-förordningen om kliniska läkemedelsprövningar^[15].
• Q97756066's has immediate cause is recorded as Q98120601^[16].
• Q97756066's cites work is recorded as Q98120601^[17].
• Q97756066's cites work is recorded as Q98120518^[18].
• Q97756066's cites work is recorded as Q97722521^[19].
• Q97756066's maintained by WikiProject is recorded as Project Riksdagen's documents^[20].
• Q97756066's copyright status is recorded as public domain^[21].
• Q97756066's legislative committee is recorded as Committee on Education^[22].

Body

Definition and Type

Q97756066's instance of is recorded as committee group motion^[6].